You are here

Home » Content

Toksik Multinodüler Guatrlı Olgularda Homosistein Düzeyi ve Lipid Peroksidasyonu

Homocysteine Levels and Lipid Peroxidation in Cases With Toxic Multinudular Goitre

Journal Name:

  • Fırat Tıp Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: Toxic multinodular goitre (TMG) is known to be a frequent endocrine pathology. Increased thyroid hormones cause excess oxygen consumption; therefore, free radical generation increases. Consequently, oxidative stress, which has been implicated in several disorders, develops. Recently, homocysteine also was shown as a prooxidant. The aim of the present study was to compare first diagnosis, pre-operative and post¬operative levels of MDA, homocysteine and thyroid hormones and to investigate the benefits of these parameters in diagnosis. Material and Method: Present study was carried out on 24 female patients diagnosed with toxic multinodular goitre; and they were divided into three groups as first diagnosis (TMG), medical treated (pre-operative; TMG-Pr) and post-operative (TMG-Po). Thyroid hormones of patients were determined with IMMULITE 2000 hormone auto-analyzer; homocysteine levels were determined by using Elx-800 system and MDA levels were determined with the manual spectrophotometric method of Satoh. Results: Homocysteine levels of TMG, TMG-Pr and TMG-Po were determined as 8.1±1.9; 10.1±1.8 and 10.5±2.6 |xmol/L, respectively. The levels of MDA were determined; there was an increase in TMG group (1.9±0.4 nmol/ml) and a decrease in TMG-Pr (1.0±0.8 nmol/ml) and TMG-Po (1.1 ±0.7 nmol/ml) groups. These two parameters were changed significantly in both TMG-Pr and TMG-Po groups, compared with TMG group (p<0.05). Conclusion: In the present study, plasma MDA levels were higher and homocysteine levels were lower in the pre-treated group compared with the treated group. These results can be due to the catabolism of homocysteine with the increased glomerular filtration rate because of the high basal metabolic activity in TMG group.©2004, Fırat Üniversitesi, Tıp Fakültesi
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Toksik multinodüler guatr (TMG) oldukça sık görülen endokrin bir patolojidir. Tiroid hormonlarındaki artış mitokondrial serbest radikal oluşumu artırmaktadır. Oksidatif stres birçok hastalığın oluşum ve gelişiminden sorumlu tutulmaktadır. Son yıllarda homosistein de prooksidan bir madde olarak gösterilmektedir. Bu çalışmanın amacı ilk tanıda, preoperatif ve cerrahi tedavi sonrası serum malondialdehit (MDA), homosistein ve tiroid hormon düzeylerini karşılaştırmak ayrıca tanıda bu parametrelerin önemini araştırmaktır. Gereç ve Yöntem: Çalışma toksik multinodüler guatr tanısı almış 24 kadın hastada yapıldı ve hastalar ilk tanı alan (TMG), medikal tedavi sonrası (preoperatif; TMG-Pr) ve operasyon sonrası (postoperatif, TMG-Po) olmak üzere 3 gruba ayrıldılar. Hastaların tiroid hormonları İMMULITE 2000 marka hormon oto analizöründe, homosistein düzeyleri ELX-800 cihazında; MDA düzeyleri ise Satoh'dan alınan manuel spektrofotometrik yönteme göre belirlenmiştir. Bulgular: TMG, TMG-Pr ve TMG-Po'da homosistein düzeyleri sırası ile 8.1±1.9; 10.1±1.8 ve 10.5±2.6 |imol/L, olarak tespit edilmiştir. TMG'li hastalarda, MDA düzeyleri artmış (1.9±0.4 nmol/ml), TMG-Pr (1.0±0.8 nmol/ml) ve TMG-Po'da (1.1±0.7 nmol/ml) ise azalma olduğu tespit edilmiştir. Her iki parametre preoperatif ve postoperatif gruplarda tedavi öncesine göre olarak anlamlı şekilde değişmektedir (p<0.05). Sonuç: Bu çalışmada TMG'li hastalarda plazma MDA düzeylerinin tedavi öncesinde, sonrasına göre yüksek; homosistein düzeylerinin ise düşük olduğu bulunmuştur. Bu sonuç; TMG grubunda artan bazal metabolik hız nedeniyle glomerular filtrasyon hızının artışına ve dolayısı ile homosisteinin daha fazla katabolize edilmesine bağlı olabilir. ©2004, Fırat Üniversitesi, Tıp Fakültesi
FULL TEXT (PDF): 
PDF icon arastirmax-toksik-multinoduler-guatrli-olgularda-homosistein-duzeyi-lipid-peroksidasyonu.pdf
  • 4
116-119
  • Turkish

REFERENCES

References: 

1. Hampel R, Kulberg T, Klein K.ve ark.. Goiter incidence in Germany is greater than previously suspected. Med Klin 1995; 90:
324-329.
2. Sundaram V, Hanna AN, Koneru L, Newman HA, Falko JM. Both hypothyroidism and hyperthyroidism enhance low density
lipoprotein oxidation. J Clin Endocrinol Metab 1997; 82: 3421¬3424.
3. Jacob RA, Burr BJ. Oxidative damage and defence. Am J Clin Nutr 1996; 63: 985-990.
4. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41: 1819-1828.
5. Stringer MD, Gorog PG, Freeman A, Kaskar VV. Lipid peroxides and atherosclerosis. BMJ 1989; 298: 281-284.
6. Wyllie AH, Duvall E. Cell injury and death. In: Mcgee JO'D, Isaacson PG, Wright NA. Oxford Textbook of Pathology. Newyork: Oxford University Press, 1992: 141-193.
7. Stampfer MJ, Osborn JA, Jaraki M. Adverse vasculer effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308¬318.
8. Hajjar KA. Homocysteine: a sulphrous fire. J Clin Invest 2001;
107: 663-664.
118
Fırat Tıp Dergisi 2004;9(4): 116-119
9. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A
quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.
JAMA 1995; 274: 1049-1057.
10. Miner SE, Evrovski J, Cole DE. Clinical chemistry and moleculer biology of homocysteine metabolism: an update. Clin Biochem
1997; 30: 189-201.
11. Brattstrom L, Israelsson B, Tengborn L, Hultberg B. Homocysteine, factor VII, and antithrombin III in subjects with different gene dosage for cystathionine p-synthase. J Inherit Metab
Dis 1989; 12: 475-482.
12. Upchurch GR, Welch GN, Freedman JE, Loscalzo J. Homocysteine attenuates endothelial glutathione peroxidase and thereby potentiates peroxide-mediated cell injury. Circulation
1995; 92: 1-28.
13. Satoh K. Serum lipid peroxide in cerebro-vascular disorders determined by a new calorimetric method. Clin Chim Acta 1978;
90: 37-43.
14. Vassev K, Olczyk K.ve ark.. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves disease during therapy. Clin Chim Acta 2000; 300: 107¬117.
Çıkım
v
e Ark.
15. Alıcıgüzel Y, Özdem SN, Özdem SS.ve ark.. Erythrocyte, plasma and serum antioxidant activities in untreated toxic multinodular
goiter patients. Free Radic Biol Med 2001; 30: 665-670.
16. Çıkım G. Koroner kalp hastalarında homosistein ile bazı lipit parametrelerinin karşılaştırılması. Uzmanlık Tezi, Elazığ: Fırat Üniversitesi, Biyokimya Anabilim Dalı, 2002.
17. Nedrebo BG, Ericsson UB, Nygard O.ve ark. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients.
Metabolism 1998; 47: 89-93.
18. Atabek ME, Pirgon O, Erkul I. Plasma homocysteine concentrations in adolescents with subclinical hypothyroidism. J Pediatr Endocrinol Metab. 2003; 16:1245-8.
19. Diekman MJ, van der Put NM, Blom HJ. ve ark. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol. 2001; 54:197-204.
20. Demirbas B, Ozkaya M, Cakal E. ve ark. Plasma homocysteine levels in hyperthyroid patients. Endocr J. 2004; 51: 121-125.

Thank you for copying data from http://www.arastirmax.com